| 1. |
Naccache JM, Gibiot Q, Monnet I, et al. Lung cancer and interstitial lung disease: a literature review. J Thorac Dis, 2018, 10(6): 3829-3844.
|
| 2. |
Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res, 2008, 68(12): 4774-4782.
|
| 3. |
Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med, 2019, 381(18): 1718-1727.
|
| 4. |
Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet, 2014, 15(2): 143-155.
|
| 5. |
Hilberg F, Tontsch-Grunt U, Baum A, et al. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. J Pharmacol Exp Ther, 2018, 364(3): 494-503.
|
| 6. |
Crestani B, Huggins J T, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med, 2019, 7(1): 60-68.
|
| 7. |
Wim A W, Francesco B, Nazia C, et al. Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON. Eur Respir J, 2021, 58(suppl 65): PA2538.
|
| 8. |
Allanore Y, Vonk M C, Distler O, et al. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. Ann Rheum Dis, 2022, 81(12): 1722-1729.
|
| 9. |
Ogura T, Takigawa N, Tomii K, et al. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respir Investig, 2019, 57(6): 512-533.
|
| 10. |
Grohé C, Wehler T, Dechow T, et al. Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO. Transl Lung Cancer Res, 2022, 11(10): 2010-2021.
|
| 11. |
Reck M, Syrigos K, Miliauskas S, et al. Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy. Lung Cancer, 2020, 148: 159-165.
|
| 12. |
Ljubicic L, Janzic U, Unk M, et al. Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis. Radiol Oncol, 2023, 57(3): 397-404.
|
| 13. |
Capelletto E, Migliorino M R, Morabito A, et al. Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. Lung Cancer, 2019, 134: 210-217.
|
| 14. |
Cascone T, Sepesi B, Lin H Y, et al. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res, 2020, 26(14): 3525-3536.
|
| 15. |
Dai W, Luo B, Wu Z, et al. A multi-center phase II study of nintedanib as second-line therapy for patients with advanced non-small-cell lung cancer in China. Am J Cancer Res, 2015, 5(10): 3270-3275.
|
| 16. |
Han J-Y, Kim H Y, Lim K Y, et al. A phase II study of nintedanib in patients with relapsed small cell lung cancer. Lung Cancer, 2016, 96: 108-112.
|
| 17. |
Kohei O, Junji K, Masahiko A, et al. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. European Respiratory Journal, 2022, 60(6): 2200380.
|
| 18. |
Ikeda S, Ogura T, Kato T, et al. Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2024.
|
| 19. |
Shiratori T, Tanaka H, Tabe C, et al. Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review. Thoracic Cancer, 2020, 11(6): 1720-1723.
|
| 20. |
Hochmair MJ, Kolb R, Wurm R, et al. Nintedanib plus Docetaxel after Immune Checkpoint Inhibitor Failure in Patients with Advanced Non-Small-Cell Lung Cancer: A Case Series. Case Reports In Oncology, 2022, 15(1): 138-148.
|
| 21. |
Dabholkar S, Gao B, Chuong B. Nintedanib-A case of treating concurrent idiopathic pulmonary fibrosis and non-small cell lung cancer. Respirology Case Reports, 2022, 10(2): e0902.
|
| 22. |
Reck M, Remon J, Hellmann M D. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2022, 40(6): 586-597.
|
| 23. |
Chen R, Shao C, Liu X, et al. Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment. Clinical and Experimental Medicine, 2023, 23(6): 2321-2330.
|
| 24. |
Rimner A, Moore Z R, Lobaugh S, et al. Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis. International Journal of Radiation Oncology, Biology, Physics, 2023, 116(5): 1091-1099.
|
| 25. |
Dy G K, Prasad D, Kumar P, et al. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer, 2021, 16(3): e19-e20.
|
| 26. |
Itano J, Kimura G, Ninomiya K, et al. Radiation-Induced Lung Injury With Lung Cancer Treated With the Combination Therapy of Nintedanib and Dexamethasone. Cureus, 2023, 15(9): e45678.
|
| 27. |
Laszlo V, Valko Z, Kovacs I, et al. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo. Clinical Cancer Research : an Official Journal of the American Association For Cancer Research, 2018, 24(15): 3729-3740.
|
| 28. |
Scagliotti G V, Gaafar R, Nowak A K, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine, 2019, 7(7): 569-580.
|
| 29. |
Wozniak A, Schneider B, Kalemkerian G, et al. A Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM). JOURNAL OF THORACIC ONCOLOGY, 2019, 14(10): S343-S343.
|
| 30. |
Varga A, Zalcman G, Gomez-Roca C, et al. Safety and Efficacy of Nintedanib in Combination with Pembrolizumab in Patients with Refractory/Relapsing Malignant Pleural. JOURNAL OF THORACIC ONCOLOGY, 2019, 14(10): S268-S268.
|
| 31. |
Bendstrup E, Wuyts W, Alfaro T, et al. Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events. Respiration; International Review of Thoracic Diseases, 2019, 97(2): 173-184.
|
| 32. |
Richeldi L, Du Bois R M, Raghu G, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370(22): 2071-2082.
|
| 33. |
Kolonics-Farkas A M, Šterclová M, Mogulkoc N, et al. Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE. Drug Safety, 2020, 43(10): 971-980.
|
